Supplementary Material and Methods

Severe asthmatics:
Severe asthmatic patients required continuous treatment with high doses of inhaled steroids (at least 1600 μg/day budesonide or beclomethasone, 800 μg/day fluticasone or equivalent).
For those taking oral steroids, the inhaled dose of steroids had to be at least 800 μg/day budesonide or beclomethasone, 400 μg/day fluticasone or equivalent. In addition, the patients had to require continuous treatment with long-acting β-agonists or oral theophylline, as documented for at least one year. As well as a baseline visit, patients taking part in the BIOAIR study also underwent a 2-week double-blind placebo-controlled oral steroid intervention, consisting of a standard course of prednisolone (0.5 mg/kg of body weight/day) added to regular treatment. Other clinical characteristics and biomarkers measured as part of the BIOAIR study included BMI, sputum and blood cell counts, exhaled NO, lung function, serum periostin, YKL-40, total IgE and CRP [1] .
Rheumatoid Arthritis Patients:
For the RA patients the Fc-glycan information were taken from published data using the mean values between anti-citrullinated peptide antibodies (ACPAs) and the remaining paired polyclonal IgGs (FT) from respective patient. For more details see Lundstrom et al. Supplemental Table S3 [2] .
Sample preparations: Serum (40 µL/sample) and BALF (500 µL/sample) of sarcoidosis patients and controls were aliquoted in triplicates. To avoid systematic errors during sample preparation and liquid chromatography tandem mass spectrometry (LC-MS/MS) analysis, each replicate set was randomized, prepared and analysed separately ( Supplementary Table 8 ). Two replicates were analysed by LC-MS/MS. The third (still available) set was confirmed to be consistent with the other two sets via pool analysis (12 replicates/pool, 6x3 pools in total). Serum (40 µL/sample) of SA patients were analysed using the same approach.
Melon Gel IgG enrichment from serum: Polyclonal IgGs were enriched from blood serum using Melon Gel IgG Spin Purification Kit (Thermo Scientific) as previously described [3] .
Briefly, 40 µL aliquots of serum were diluted with Melon Gel Purification Buffer (1:10). 500 µL of Melon gel slurry/sample were washed twice with 300 µL purification buffer (30 s at 2,500 × g). The samples were added to the Melon Gel columns and incubated at 20 C for 30 min using end-over-end mixing. The IgG-molecules with associated proteins were collected via centrifugation (60 s at 2,500 × g).
Melon Gel IgG enrichment from BAL-fluid: Prior sample preparation 20 µL of 25× stock solution of cOmplete EDTA free protease inhibitor cocktail EASYpacks (Sigma Aldrich) was added to 500 µL BALF. Samples were then dried down to approximately 50 uL in speedvac (7 hours, 30 C). Samples were stored at -80 C until Melon Gel extraction. Samples were re-dissolved in Melon Gel Buffer to a final volume of 500 µL. In a first step, polyclonal IgGs were enriched using the same procedure as described above for the MG-IgG serum enrichment. Due to high saline (NaCl, 0,9%) concentration in the BALF, samples then underwent a desalting procedure using Zeba™ Spin Columns, 7K MWCO, 2 ml (Thermo Fisher Scientific) in accordance to manufacturer's instructions, apart from using Melon Gel as samples buffer. The MG-extraction was repeated to improve the IgG sample purity. Note that this approach 1) IgG-MG-enrichment, 2) Desalting, 3) IgG-MG-enrichment, vastly improves reproducibility and IgG purity of the enriched sample compared to the alternative approach (i.e.
Desalting followed by IgG-MG enrichment). Samples were dried down to 30 uL /sample (4 hours, 30 C) and stored at -80 C until trypsin digestion.
IgG-sample trypsin digestion: Samples were treated similar to what has previously been described [3] .
For serum IgG, ten µg of IgG/sample and for BALF the complete IgG samples were dissolved to a final volume of 70 µL with a final concentration of 50 mM ammonium bicarbonate (pH 8). The protein was reduced (5 mM dithiothreitol, 30 min, 56 C) and alkylated (14 mM iodoacetamide, 30 min in darkness). Trypsin was added in a ratio of 1:50 (enzyme:protein) for overnight digestion at 37 C. Peptides were then desalted using C18 HyperSep Filer Plates (Thermo Fisher Scientific, Waltham, MA). For peptide elution, 60% acetonitrile in 0.1% formic acid was used. Samples were dried using SpeedVac and stored at -20 C until LC-MS/MS analysis.
LC-MS/MS analysis:
Samples were re-suspended in 0.1% formic acid and 0.5% acetonitrile solution and injected on the column in 5 µL aliquots containing 1.0 µg of digest. Due to time limitations, only two of the replicates were analysed, (the third set is still available for further evaluation and has been confirmed to be reproducible with the other sets via analysis of pools). An EASY-nLC system connected in-line to a Fusion Orbitrap mass spectrometer (both -ThermoFisher Scientific) was used.
Reversed phase nano-LC-separation of the peptides was performed on a 50 cm long EASY spray column (PepMap, C18, 2 µm, 100 Å). The chromatographic separation was achieved using a gradient 
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Multivariate OPLS-DA modelling BALF and serum differences:
) was obtained when distinguishing BALF and serum Fc-glycan profiles. Noteworthy, 31 glycans (ten from IgG 1 , twelve from IgG 2/(3) and nine from IgG 4 ) were correlating with 95% confidence with serum compared to only five Fc-glycans (three from IgG 2/(3) and two from IgG 4 ) correlating with BALF ( Supplementary Table 5 ). This observation may indicate that IgGs from serum are more heterogeneous in their Fc-glycan composition compared to IgGs from BALF. However, the dissimilarities may also be due to differences in IgG enrichment procedures. Univariate statistical data also confirmed a higher prevalence of low abundant glycoforms in serum ( Supplementary Table 4) with the biggest differences (p<0.001) observed in higher abundance of mono-antennary and bisected forms ( Supplementary Table 4 ). Supplemental Table 1 . Full patient characteristics across five study groups. Figure 1 .
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LS
P-values were FDR corrected according to total number of comparisons (n=479) in the study.
Yellow p: 0.05-0.001 Red p: 0.001> Columns two to four summarize the glycan and which IgG isoform it originates from followed by the predictive component pq [1] and the 95% confidence interval. Glycan nomenclature is described in Figure 1 . to distinguish which Fc-glycans correlated with each specific group. Note that the model only generated one predictive axis with the non-LS and LS vectors anti-correlating with the healthy subgroup. Columns two to four summarize the glycan and which IgG isoform it originates from followed by the predictive component pq [1] and the 95% confidence interval. Glycan nomenclature is described in Figure 1 . 12_1  28_2  11_3  s_31_1  s_22_2  s_18_3  47  Male  Sarkoidos  -non-smoker   0001012  A15  16_1  17_2  15_3  s_23_1  s_25_2  s_15_3  43  Male  Sarkoidos  -ex-smoker   0001016  A35  6_1  14_2  25_3  s_7_1  s_2_2  s_35_3  38  Male  Sarkoidos  -non-smoker   0001021  A26  21_1  33_2  31_3  s_13_1  s_14_2  s_26_3  44  Male  Sarkoidos  -non-smoker   0001024  A14  19_1  5_2  33_3  s_28_1  s_19_2  s_14_3  43  Male  Sarkoidos  -non-smoker   0001030  A3  22_1  26_2  28_3  s_20_1  s_7_2  s_3_3  53  Male  Sarkoidos  -non-smoker   0001039  A12  8_1  36_2  17_3  s_26_1  s_13_2  s_12_3  33  Male  Sarkoidos  -non-smoker   0001049  A11  34_1  3_2  12_3  s_12_1  s_33_2  s_11_3  35  Male  Sarkoidos  -ex-smoker   0000503  A7  29_1  18_2  4_3  s_4_1  s_27_2  s_7_3  40  Male  Sarkoidos  +  non-smoker   0000507  A30  18_1  11_2  13_3  s_2_1  s_35_2  s_30_3  49  Male  Sarkoidos  +  non-smoker   0000774  A29  33_1  2_2  26_3  s_8_1  s_15_2  s_29_3  44  Male  Sarkoidos  +  non-smoker   0000870*  A17*  5_1  21_2  14_3  s_14_1  s_21_2  s_17_3  46  Male  Sarkoidos  +  non-smoker   0000902  A34  15_1  27_2  29_3  s_34_1  s_6_2  s_34_3  28  Male  Sarkoidos  +  ex-smoker   0000930  A27  3_1  10_2  8_3  s_16_1  s_23_2  s_27_3  41  Male  Sarkoidos  +  non-smoker   0000971  A21  26_1  16_2  16_3  s_15_1  s_36_2  s_21_3  43  Male  Sarkoidos  +  non-smoker   0001031*  A8*  31_1  34_2  10_3  s_18_1  s_4_2  s_8_3  47  Male  Sarkoidos  +  non-smoker   0001046  A22  23_1  4_2  34_3  s_32_1  s_3_2  s_22_3  36  Male  Sarkoidos  +  non-smoker   0001079  A6  13_1  8_2  23_3  s_1_1  s_20_2  s_6_3  54  Male  Sarkoidos  +  ex-smoker   0001088  A25  24_1  32_2  20_3  s_21_1  s_30_2  s_25_3  34  Male  Sarkoidos  +  ex-smoker   0001124  A1  1_1  19_2  3_3  s_24_1  s_28_2  s_1_3  36  Male  Sarkoidos  +  non-smoker   0000266  A2  20_1  25_2  2_3  s_9_1  s_11_2  s_2_3  27  Male  Healthy  NA  non-smoker   0000274  A20  9_1  12_2  21_3  s_19_1  s_24_2  s_20_3  27  Male  Healthy  NA  non-smoker   0000276  A9  17_1  7_2  35_3  s_10_1  s_31_2  s_9_3  25  Male  Healthy  NA  non-smoker   0000292  A10  36_1  6_2  18_3  s_6_1  s_32_2  s_10_3  25  Male  Healthy  NA  non-smoker   0000677  A5  2_1  22_2  6_3  s_27_1  s_29_2  s_5_3  28  Male  Healthy  NA  non-smoker   0000685  A28  7_1  30_2  36_3  s_29_1  s_16_2  s_28_3  27  Male  Healthy  NA  non-smoker   0000788  A16  35_1  20_2  32_3  s_30_1  s_8_2  s_16_3  29  Male  Healthy  NA  non-smoker  0000790  A19  32_1  31_2  7_3  s_33_1  s_9_2  s_19_3  24  Male  Healthy  NA  non-smoker   0000791  A4  30_1  35_2  9_3  s_11_1  s_34_2  s_4_3  22  Male  Healthy  NA  non-smoker   0000879  A24  25_1  24_2  19_3  s_25_1  s_26_2  s_24_3  24  Male  Healthy  NA  non-smoker   0001132  A13  11_1  9_2  27_3  s_22_1  s_5_2  s_13_3  35  Male  Healthy  NA  non-smoker   0001259  A32  28_1  15_2  1_3  s_5_1  s_18_2  s_32_3  27  Male  Healthy  NA non-smoker * Same patient, sampled twice with one year between sampling dates
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